Small-Diameter Transjugular Intrahepatic Portosystemic Shunt versus Endoscopic Variceal Ligation Plus Propranolol for Variceal Rebleeding in Advanced Cirrhosis
- PMID: 37606572
- DOI: 10.1148/radiol.223201
Small-Diameter Transjugular Intrahepatic Portosystemic Shunt versus Endoscopic Variceal Ligation Plus Propranolol for Variceal Rebleeding in Advanced Cirrhosis
Abstract
Background Some studies have shown that transjugular intrahepatic portosystemic shunt (TIPS) placement within 72 hours of admission improves survival in patients at high risk who present with acute variceal bleeding. However, the role of small-diameter covered TIPS in the secondary prophylaxis of variceal bleeding is still debatable. Purpose To compare the efficacy of 8-mm TIPS and endoscopic variceal ligation (EVL) plus propranolol in the prevention of variceal rebleeding among participants with advanced cirrhosis. Materials and Methods Between June 2015 and December 2018, participants admitted to the hospital for variceal bleeding were considered for enrollment in this randomized controlled trial (ClinicalTrials.gov). Participants with Child-Pugh class B or C cirrhosis were randomly assigned to receive an 8-mm covered TIPS or EVL and propranolol. The primary end point was recurrent variceal bleeding assessed using Kaplan-Meier curve analysis. Secondary end points included survival and overt hepatic encephalopathy (HE) assessed using Kaplan-Meier curve analysis. Results A total of 100 participants were enrolled, with 50 randomly assigned to the EVL plus propranolol group (median age, 54 years; IQR, 45-60 years; 29 male, 21 female) and 50 randomly assigned to the TIPS group (median age, 49 years; IQR, 43-56 years; 32 male, 18 female). The median follow-up period was 43.4 months. In the TIPS group, variceal rebleeding risk was reduced compared with variceal rebleeding risk in the EVL plus propranolol group (hazard ratio [HR], 0.31; 95% CI: 0.14, 0.69; P = .008), but the incidence of overt HE was higher in the TIPS group (30.0% vs 16.0%, P = .03). No differences in survival were observed between the two groups (1-year survival: TIPS, 98.0%; EVL plus propranolol, 92.0%; 3-year survival: TIPS, 94.0%; EVL plus propranolol, 85.7%; HR, 0.52; 95% CI: 0.19, 1.42; P = .22). Conclusion When compared with EVL plus propranolol, 8-mm TIPS led to reduced variceal rebleeding but did not impact overall survival in participants with Child-Pugh class B or C cirrhosis. Clinical trial registration no. NCT02477384 © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Barth in this issue.
Comment in
-
Transjugular Intrahepatic Portosystemic Shunt versus Endoscopic Variceal Ligation, an Unequal Competition.Radiology. 2023 Aug;308(2):e231774. doi: 10.1148/radiol.231774. Radiology. 2023. PMID: 37606568 No abstract available.
Similar articles
-
Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial.Gut. 2018 Dec;67(12):2156-2168. doi: 10.1136/gutjnl-2017-314634. Epub 2017 Sep 28. Gut. 2018. PMID: 28970291 Clinical Trial.
-
Transjugular intrahepatic portosystemic shunt prevents rebleeding in cirrhotic patients having cavernous transformation of the portal vein without improving their survival.J Dig Dis. 2019 Feb;20(2):89-96. doi: 10.1111/1751-2980.12702. Epub 2019 Mar 3. J Dig Dis. 2019. PMID: 30629804
-
Endoscopic variceal ligation plus propranolol vs. transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial.Endoscopy. 2002 Sep;34(9):690-7. doi: 10.1055/s-2002-33565. Endoscopy. 2002. PMID: 12195325 Clinical Trial.
-
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis.Cochrane Database Syst Rev. 2020 Oct 22;10(10):CD000553. doi: 10.1002/14651858.CD000553.pub3. Cochrane Database Syst Rev. 2020. PMID: 33089892 Free PMC article.
-
Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhage in people with cirrhosis.Cochrane Database Syst Rev. 2018 Oct 31;10(10):CD001023. doi: 10.1002/14651858.CD001023.pub3. Cochrane Database Syst Rev. 2018. PMID: 30378107 Free PMC article.
Cited by
-
Sequential endoscopic treatment for esophageal and gastric variceal bleeding significantly reduces patient mortality and rebleeding rates.Therap Adv Gastroenterol. 2024 Nov 14;17:17562848241299743. doi: 10.1177/17562848241299743. eCollection 2024. Therap Adv Gastroenterol. 2024. PMID: 39553446 Free PMC article.
-
Carvedilol and traditional nonselective beta blockers for the secondary prophylaxis of variceal hemorrhage and portal hypertension related complications among patients with decompensated cirrhosis: a systematic review and network meta-analysis.Hepatol Int. 2025 Jun;19(3):647-661. doi: 10.1007/s12072-025-10812-8. Epub 2025 Apr 3. Hepatol Int. 2025. PMID: 40178720
-
Comprehensive approach to esophageal variceal bleeding: From prevention to treatment.World J Gastroenterol. 2024 Nov 21;30(43):4602-4608. doi: 10.3748/wjg.v30.i43.4602. World J Gastroenterol. 2024. PMID: 39575399 Free PMC article. Review.
-
Association between overt hepatic encephalopathy and liver pathology after transjugular intrahepatic portosystemic shunt creation in cirrhotic patients.Sci Rep. 2025 Jan 9;15(1):1548. doi: 10.1038/s41598-025-86176-8. Sci Rep. 2025. PMID: 39789163 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical